Osteoboost Health has announced that the United States Patent and Trademark Office (USPTO) has awarded the company its sixth U.S. patent (No. 12,232,993) for Osteoboost, a wearable device designed to treat osteopenia and improve bone health through targeted vibration therapy. The device is the first and only FDA-cleared, non-drug prescription treatment for low bone density.
The newly issued patent, titled “Wearable Apparatus for the Treatment or Prevention of Osteopenia and Osteoporosis, Stimulating Bone Growth, Preserving or Improving Bone Mineral Density, and Inhibiting Adipogenesis,” covers key innovations including:
- A wearable vibrating apparatus that delivers mechanical stimulation to bones, helping preserve and improve bone density
- Integrated accelerometers to monitor treatment effectiveness and ensure compliance
- Advanced tracking and reminder features for personalized bone health management
Powered by NASA-inspired technology, the Osteoboost wearable belt targets high-risk areas like the lumbar spine and hips, using a proprietary vibration frequency to stimulate bone growth. The device incorporates two embedded sensors that calibrate the vibration dose at the beginning of each treatment session, ensuring that every session provides a therapeutic dose of vibration to the patient.
“Osteoboost is pioneering a new standard of care for individuals at risk of osteoporosis,” said Laura Yecies, CEO of Osteoboost Health, Inc. “This patent underscores our commitment to innovation and validates the groundbreaking technology behind Osteoboost. By providing a non-drug solution backed by clinical research, we will empower millions of people with osteopenia to take control of their bone health.”
According to the company, clinical trials have shown promising results for the device, including up to 85% reduction in spine bone density loss and 55% reduction in hip bone density loss. The company also offers a virtual platform with workouts, fall risk assessments, and continuous education to empower users to manage their bone health.
The company has also announced a name change from Bone Health Technologies to Osteoboost Health, Inc. to streamline corporate and product branding. The Osteoboost device is expected to launch in Q2 2025.
